[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Ruxolitinib.]
[J01GA01, streptomycin, Ruxolitinib may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ruxolitinib.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Ruxolitinib.]
[L04AA27, fingolimod, Ruxolitinib may increase the immunosuppressive activities of Fingolimod.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01CG01, sulbactam, Ruxolitinib may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The metabolism of Ruxolitinib can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Ruxolitinib can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ruxolitinib.]
[J01EC03, sulfamoxole, The metabolism of Ruxolitinib can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Ruxolitinib can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Ruxolitinib can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Ruxolitinib can be decreased when combined with Sulfisoxazole.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Ruxolitinib.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ruxolitinib.]
[L02BA01, tamoxifen, The metabolism of Ruxolitinib can be increased when combined with Tamoxifen.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01CB02, teniposide, The metabolism of Ruxolitinib can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G03BA03, testosterone, The metabolism of Ruxolitinib can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Ruxolitinib can be decreased when combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A04AD10, dronabinol, The metabolism of Ruxolitinib can be decreased when combined with Dronabinol.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ruxolitinib.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Ruxolitinib.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Ruxolitinib.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Ruxolitinib.]
[G04BE06, moxisylyte, Ruxolitinib may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Ruxolitinib.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Ruxolitinib.]
[N05AL03, tiapride, Ruxolitinib may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The metabolism of Ruxolitinib can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, Ruxolitinib may increase the bradycardic activities of Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01AA12, tobramycin, Ruxolitinib may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[V04CA01, tolbutamide, Tolbutamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06AF04, tranylcypromine, The metabolism of Ruxolitinib can be decreased when combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Ruxolitinib.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Ruxolitinib.]
[S01BA05, triamcinolone, The metabolism of Ruxolitinib can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Triethylenetetramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Ruxolitinib.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Fluclorolone.]
[R03BA07, mometasone, The metabolism of Ruxolitinib can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Ruxolitinib may increase the bradycardic activities of Trimebutine.]
[N03AC02, trimethadione, Ruxolitinib may increase the bradycardic activities of Trimethadione.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06AA06, trimipramine, The metabolism of Ruxolitinib can be decreased when combined with Trimipramine.]
[J01FA08, troleandomycin, The metabolism of Ruxolitinib can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Ruxolitinib.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Belimumab.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[R02AA14, oxyquinoline, Ruxolitinib may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The metabolism of Ruxolitinib can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Ruxolitinib can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Ruxolitinib can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Ruxolitinib can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Ruxolitinib.]
[S01AA28, vancomycin, Ruxolitinib may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Ruxolitinib.]
[N03AX21, ezogabine, Ezogabine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AF01, rivaroxaban, Rivaroxaban may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AC24, ticagrelor, The metabolism of Ruxolitinib can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, Ruxolitinib may increase the bradycardic activities of Verapamil.]
[N06AX09, viloxazine, The metabolism of Ruxolitinib can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Ruxolitinib can be increased when combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Ruxolitinib.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Ruxolitinib.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ruxolitinib.]
[A11HA03, vitamin E, The metabolism of Ruxolitinib can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The metabolism of Ruxolitinib can be increased when combined with Warfarin.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Ruxolitinib.]
[N05AF05, zuclopenthixol, The metabolism of Ruxolitinib can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Ruxolitinib can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Ruxolitinib can be increased when combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Ruxolitinib can be decreased when combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B06AC02, icatibant, Icatibant may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Ruxolitinib can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Ruxolitinib.]
[R03DC01, zafirlukast, The metabolism of Ruxolitinib can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05AE04, ziprasidone, The metabolism of Ruxolitinib can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Ruxolitinib can be decreased when combined with Drospirenone.]
[V03AC02, deferiprone, Deferiprone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ruxolitinib.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Ruxolitinib.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Ruxolitinib can be decreased when combined with Fusidic acid.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Tolterodine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DH04, doripenem, Doripenem may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C07AB03, atenolol, Ruxolitinib may increase the bradycardic activities of Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ruxolitinib.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Ruxolitinib.]
[J02AC03, voriconazole, The metabolism of Ruxolitinib can be decreased when combined with Voriconazole.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Ruxolitinib can be decreased when combined with Vismodegib.]
[R07AX02, ivacaftor, The metabolism of Ruxolitinib can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Ruxolitinib can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ruxolitinib.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Ruxolitinib.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Ruxolitinib.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ruxolitinib.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Ruxolitinib.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Ruxolitinib.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ruxolitinib.]
[A08AA11, lorcaserin, Lorcaserin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD12, mirabegron, Ruxolitinib may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Ruxolitinib can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Ruxolitinib can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Ruxolitinib can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Ruxolitinib can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Ruxolitinib.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Ruxolitinib.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Ruxolitinib.]
[L01EX05, regorafenib, Ruxolitinib may increase the bradycardic activities of Regorafenib.]
[N05CA04, barbital, The metabolism of Ruxolitinib can be increased when combined with Barbital.]
[D02BA02, octinoxate, Ruxolitinib may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Ruxolitinib can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Bendamustine is combined with Ruxolitinib.]
[N04BD02, rasagiline, Rasagiline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C08CA13, lercanidipine, Ruxolitinib may increase the bradycardic activities of Lercanidipine.]
[N06DA02, donepezil, Ruxolitinib may increase the bradycardic activities of Donepezil.]
[N03AX22, perampanel, The metabolism of Ruxolitinib can be increased when combined with Perampanel.]
[L04AA29, tofacitinib, Ruxolitinib may increase the immunosuppressive activities of Tofacitinib.]
[V09IX04, fluorodeoxyglucose F18, Ruxolitinib may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[L01EX07, cabozantinib, The metabolism of Ruxolitinib can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, Ruxolitinib may increase the bradycardic activities of Pasireotide.]
[G04BE03, sildenafil, The metabolism of Ruxolitinib can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Gadofosveset trisodium may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ponatinib.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Apixaban is combined with Ruxolitinib.]
[A16AX08, teduglutide, Ruxolitinib may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Ruxolitinib can be decreased when combined with Lomitapide.]
[C04AX11, bencyclane, Ruxolitinib may increase the bradycardic activities of Bencyclane.]
[A10BH04, alogliptin, Alogliptin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Ruxolitinib can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Ruxolitinib may increase the bradycardic activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Ruxolitinib can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Dimethyl fumarate.]
[M04AB03, benzbromarone, The metabolism of Ruxolitinib can be decreased when combined with Benzbromarone.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Ruxolitinib.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Benzocaine.]
[L03AA12, ancestim, Ruxolitinib may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Everolimus is combined with Ruxolitinib.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01EE01, trametinib, Ruxolitinib may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ruxolitinib.]
[V09AX05, florbetapir F-18, Ruxolitinib may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Ruxolitinib may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C08EA02, bepridil, Ruxolitinib may increase the bradycardic activities of Bepridil.]
[L03AA14, lipegfilgrastim, Ruxolitinib may increase the myelosuppressive activities of Lipegfilgrastim.]
[A10BJ03, lixisenatide, Ruxolitinib may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Ruxolitinib may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ibrutinib.]
[N06AX26, vortioxetine, Ruxolitinib may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The metabolism of Ruxolitinib can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Ruxolitinib can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Ruxolitinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Droxidopa may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C07AB04, acebutolol, Ruxolitinib may increase the bradycardic activities of Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Ruxolitinib can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Ruxolitinib can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Ruxolitinib can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Ruxolitinib can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Ruxolitinib can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, Ruxolitinib may increase the bradycardic activities of Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Ruxolitinib.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AC11, siltuximab, The metabolism of Ruxolitinib can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Ruxolitinib may increase the bradycardic activities of Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Ruxolitinib can be decreased when combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Ruxolitinib.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Ruxolitinib.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Idelalisib.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Ruxolitinib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05CM19, suvorexant, The metabolism of Ruxolitinib can be decreased when combined with Suvorexant.]
[J01XA05, oritavancin, The metabolism of Ruxolitinib can be increased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Ruxolitinib.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ruxolitinib.]
[L01EX09, nintedanib, The metabolism of Ruxolitinib can be decreased when combined with Nintedanib.]
[S03AA06, gentamicin, Ruxolitinib may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Blinatumomab.]
[L01XK01, olaparib, The metabolism of Ruxolitinib can be decreased when combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Ruxolitinib.]
[B01AF03, edoxaban, Ruxolitinib may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The metabolism of Ruxolitinib can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Ruxolitinib can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Ruxolitinib can be decreased when combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Panobinostat is combined with Ruxolitinib.]
[N02BE01, acetaminophen, The metabolism of Ruxolitinib can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Ruxolitinib.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Ruxolitinib.]
[C01EB17, ivabradine, Ruxolitinib may increase the bradycardic activities of Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Ruxolitinib can be increased when combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Ruxolitinib.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01EC01, acetazolamide, The metabolism of Ruxolitinib can be decreased when combined with Acetazolamide.]
[A02BC03, lansoprazole, The metabolism of Ruxolitinib can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Ruxolitinib may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Trabectedin is combined with Ruxolitinib.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Ruxolitinib.]
[J02AC05, isavuconazole, The metabolism of Ruxolitinib can be increased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Ruxolitinib can be decreased when combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ruxolitinib.]
[L01EE02, cobimetinib, The metabolism of Ruxolitinib can be decreased when combined with Cobimetinib.]
[L01XG03, ixazomib, Ruxolitinib may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, The metabolism of Ruxolitinib can be decreased when combined with Acetohexamide.]
[M04AB05, lesinurad, The metabolism of Ruxolitinib can be increased when combined with Lesinurad.]
[N05CA05, aprobarbital, The metabolism of Ruxolitinib can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N03AX23, brivaracetam, Brivaracetam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Ruxolitinib can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Bromazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Ruxolitinib may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C08CA01, amlodipine, Ruxolitinib may increase the bradycardic activities of Amlodipine.]
[N05AX17, pimavanserin, The metabolism of Ruxolitinib can be decreased when combined with Pimavanserin.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Bupivacaine.]
[C07AA19, bupranolol, Ruxolitinib may increase the bradycardic activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Ruxolitinib can be decreased when combined with Buprenorphine.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Ruxolitinib.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ruxolitinib.]
[N06DA03, rivastigmine, Ruxolitinib may increase the bradycardic activities of Rivastigmine.]
[P01BE02, artemether, The metabolism of Ruxolitinib can be decreased when combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01GX07, azelastine, The metabolism of Ruxolitinib can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Ruxolitinib can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Ruxolitinib can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Ruxolitinib can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ocrelizumab.]
[A06AH05, naldemedine, Ruxolitinib may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Ruxolitinib may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Ruxolitinib may increase the bradycardic activities of Pregabalin.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Ruxolitinib can be increased when combined with Calcitriol.]
[P01CA02, benznidazole, Ruxolitinib may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ruxolitinib.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Ruxolitinib.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Ruxolitinib can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Ruxolitinib.]
[N07XX13, valbenazine, Ruxolitinib may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Ruxolitinib can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Ruxolitinib can be decreased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Ruxolitinib.]
[L04AC14, sarilumab, The metabolism of Ruxolitinib can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The metabolism of Ruxolitinib can be increased when combined with Delafloxacin.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Ruxolitinib.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Ruxolitinib can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The metabolism of Ruxolitinib can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Ruxolitinib can be increased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Ruxolitinib.]
[C07AB07, bisoprolol, Ruxolitinib may increase the bradycardic activities of Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Ruxolitinib can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C07AA17, bopindolol, Ruxolitinib may increase the bradycardic activities of Bopindolol.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Ruxolitinib.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ruxolitinib.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Ruxolitinib.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The metabolism of Ruxolitinib can be increased when combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Ruxolitinib.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01EL02, acalabrutinib, The metabolism of Ruxolitinib can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Ruxolitinib can be decreased when combined with Letermovir.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Ruxolitinib may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, The metabolism of Ruxolitinib can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Ruxolitinib can be increased when combined with Carbamazepine.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Ruxolitinib.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ruxolitinib.]
[C07AG02, carvedilol, Ruxolitinib may increase the bradycardic activities of Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Ruxolitinib can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Ruxolitinib can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Ruxolitinib can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Baricitinib.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01GB14, plazomicin, Ruxolitinib may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Ruxolitinib may increase the bradycardic activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Ruxolitinib can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Ruxolitinib can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Ruxolitinib can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Ruxolitinib can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The metabolism of Ruxolitinib can be decreased when combined with Dacomitinib.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Ruxolitinib.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Ruxolitinib may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01ED05, lorlatinib, The metabolism of Ruxolitinib can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Ruxolitinib can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Ruxolitinib.]
[L01EX13, gilteritinib, The metabolism of Ruxolitinib can be decreased when combined with Gilteritinib.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ravulizumab.]
[A06AX05, prucalopride, Prucalopride may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Ruxolitinib.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Ruxolitinib.]
[P02BX04, triclabendazole, The metabolism of Ruxolitinib can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Ruxolitinib can be increased when combined with Esketamine.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Ruxolitinib can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Ruxolitinib may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Ruxolitinib.]
[N05BA09, clobazam, The metabolism of Ruxolitinib can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Ruxolitinib can be increased when combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Ruxolitinib can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Ruxolitinib can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Ruxolitinib can be increased when combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Ruxolitinib can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Upadacitinib.]
[N07XX11, pitolisant, The serum concentration of Ruxolitinib can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Ruxolitinib can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The serum concentration of Ruxolitinib can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Ruxolitinib.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DB01, cephalexin, The metabolism of Ruxolitinib can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DB09, cephradine, The metabolism of Ruxolitinib can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Ruxolitinib can be increased when combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Ruxolitinib.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Ruxolitinib.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Diroximel fumarate.]
[G03AC09, desogestrel, The metabolism of Ruxolitinib can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Ruxolitinib can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Ruxolitinib can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M09AX08, golodirsen, Ruxolitinib may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Ruxolitinib may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Ruxolitinib can be decreased when combined with Avapritinib.]
[L01XX72, tazemetostat, The metabolism of Ruxolitinib can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ruxolitinib.]
[M01AX21, diacetylrhein, The metabolism of Ruxolitinib can be decreased when combined with Diacerein.]
[J05AB16, remdesivir, The metabolism of Ruxolitinib can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Ruxolitinib can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Ruxolitinib can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Ruxolitinib.]
[R02AA03, dichlorobenzyl alcohol, Ruxolitinib may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Ruxolitinib may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[N02CC06, eletriptan, The metabolism of Ruxolitinib can be decreased when combined with Eletriptan.]
[M01AH02, rofecoxib, The metabolism of Ruxolitinib can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Ruxolitinib can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, Ruxolitinib may increase the bradycardic activities of Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Ruxolitinib can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Ruxolitinib can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ruxolitinib.]
[S03AA08, chloramphenicol, The metabolism of Ruxolitinib can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Ruxolitinib.]
[D07XB03, fluprednidene, The metabolism of Ruxolitinib can be increased when combined with Fluprednidene.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Ruxolitinib.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Ruxolitinib is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Ruxolitinib.]
[R06AX22, ebastine, The metabolism of Ruxolitinib can be decreased when combined with Ebastine.]
[P01BB01, proguanil, The metabolism of Ruxolitinib can be decreased when combined with Proguanil.]
[L04AC19, satralizumab, The serum concentration of Ruxolitinib can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01EX23, pralsetinib, The metabolism of Ruxolitinib can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA01, chlorpromazine, The metabolism of Ruxolitinib can be increased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N02BA03, choline salicylate, Ruxolitinib may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, Ruxolitinib may increase the bradycardic activities of Vinpocetine.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B06AC06, berotralstat, The serum concentration of Ruxolitinib can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Ruxolitinib can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Ruxolitinib.]
[M01AX25, chondroitin sulfates, Ruxolitinib may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Ruxolitinib can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Ruxolitinib can be decreased when combined with Tepotinib.]
[N03AX10, felbamate, The metabolism of Ruxolitinib can be increased when combined with Felbamate.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[R03BA03, flunisolide, The metabolism of Ruxolitinib can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Ruxolitinib can be increased when combined with Fluocinolone acetonide.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Ruxolitinib can be decreased when combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ponesimod.]
[L03AB10, peginterferon alfa-2b, The metabolism of Ruxolitinib can be increased when combined with Peginterferon alfa-2b.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Ruxolitinib.]
[A02BA01, cimetidine, The metabolism of Ruxolitinib can be decreased when combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N07CA02, cinnarizine, Ruxolitinib may increase the bradycardic activities of Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Ruxolitinib can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Ruxolitinib can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Ruxolitinib can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ruxolitinib.]
[N06AB04, citalopram, The metabolism of Ruxolitinib can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pegcetacoplan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Ruxolitinib can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Ruxolitinib can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Ruxolitinib can be decreased when it is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Ioflupane I-123 may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Ruxolitinib may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Ruxolitinib may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[L04AA59, avacopan, The metabolism of Ruxolitinib can be decreased when combined with Avacopan.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A10BB12, glimepiride, The metabolism of Ruxolitinib can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Ruxolitinib can be decreased when combined with Gliquidone.]
[N06AX25, St. John's wort extract, The metabolism of Ruxolitinib can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Ruxolitinib can be increased when it is combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Ruxolitinib.]
[J04BA01, clofazimine, The metabolism of Ruxolitinib can be decreased when combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Ruxolitinib.]
[C10AB01, clofibrate, The metabolism of Ruxolitinib can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Ruxolitinib can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Ruxolitinib can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, Clomipramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01EA04, clonidine, Ruxolitinib may increase the bradycardic activities of Clonidine.]
[C01EB24, mavacamten, The serum concentration of Ruxolitinib can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Deucravacitinib.]
[A04AA01, ondansetron, The metabolism of Ruxolitinib can be decreased when combined with Ondansetron.]
[J05AX31, lenacapavir, The metabolism of Ruxolitinib can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Ruxolitinib is combined with Clozapine.]
[J01GB12, arbekacin, Ruxolitinib may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[H01AC08, somatrogon, The metabolism of Ruxolitinib can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Ruxolitinib can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01XB01, colistin, Ruxolitinib may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Leflunomide.]
[A04AA03, tropisetron, Ruxolitinib may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Ruxolitinib.]
[J01FA15, telithromycin, The metabolism of Ruxolitinib can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Ruxolitinib.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Ruxolitinib.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C05BB03, invert sugar, Ruxolitinib may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[V08AB05, iopromide, Ruxolitinib may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Ruxolitinib may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Ruxolitinib may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The metabolism of Ruxolitinib can be decreased when combined with Valdecoxib.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J02AC02, itraconazole, The metabolism of Ruxolitinib can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Ruxolitinib.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05BA10, ketazolam, The metabolism of Ruxolitinib can be decreased when combined with Ketazolam.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01EA01, imatinib, The serum concentration of Ruxolitinib can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Ruxolitinib can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Ruxolitinib may increase the bradycardic activities of Lacidipine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ruxolitinib.]
[N03AX09, lamotrigine, Ruxolitinib may increase the bradycardic activities of Lamotrigine.]
[S01BA03, cortisone, The metabolism of Ruxolitinib can be increased when combined with Cortisone.]
[N07BC04, lofexidine, Lofexidine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Ruxolitinib may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Ruxolitinib may increase the bradycardic activities of Manidipine.]
[C07AA14, mepindolol, Ruxolitinib may increase the bradycardic activities of Mepindolol.]
[H02AB15, meprednisone, The metabolism of Ruxolitinib can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Ruxolitinib can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C04AX01, cyclandelate, Ruxolitinib may increase the bradycardic activities of Cyclandelate.]
[R06AE03, cyclizine, The metabolism of Ruxolitinib can be decreased when combined with Cyclizine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Ruxolitinib may decrease the excretion rate of Melperone which could result in a higher serum level.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Ruxolitinib.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA03, midecamycin, The metabolism of Ruxolitinib can be decreased when combined with Midecamycin.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Ruxolitinib can be increased when combined with Cyclophosphamide.]
[S01XA18, cyclosporine, Ruxolitinib may increase the immunosuppressive activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Ruxolitinib can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, The metabolism of Ruxolitinib can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Ruxolitinib can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ruxolitinib.]
[M01AH05, etoricoxib, The metabolism of Ruxolitinib can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ruxolitinib.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ruxolitinib.]
[G03XA01, danazol, The metabolism of Ruxolitinib can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Ruxolitinib can be increased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Ruxolitinib can be decreased when combined with Daunorubicin.]
[A04AD11, nabilone, The metabolism of Ruxolitinib can be decreased when combined with Nabilone.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C07AB12, nebivolol, Ruxolitinib may increase the bradycardic activities of Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Ruxolitinib can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Ruxolitinib may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, The metabolism of Ruxolitinib can be decreased when combined with Nilutamide.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ruxolitinib.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06AA01, desipramine, The metabolism of Ruxolitinib can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Ruxolitinib.]
[V04CH02, indigo carmine, Ruxolitinib may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ruxolitinib.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The metabolism of Ruxolitinib can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Ruxolitinib can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Ruxolitinib can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Ruxolitinib can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Ruxolitinib can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Ruxolitinib can be decreased when combined with Paramethadione.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Ruxolitinib.]
[N06AB05, paroxetine, The metabolism of Ruxolitinib can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Ruxolitinib can be decreased when combined with Clopidogrel.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Cinchocaine.]
[R05DA08, pholcodine, Ruxolitinib may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01CF01, dicloxacillin, The metabolism of Ruxolitinib can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A03AX04, pinaverium, Ruxolitinib may increase the bradycardic activities of Pinaverium.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Ixabepilone is combined with Ruxolitinib.]
[L01EB02, erlotinib, The metabolism of Ruxolitinib can be decreased when combined with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pirarubicin.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AA01, diethylstilbestrol, The metabolism of Ruxolitinib can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, Ruxolitinib may increase the bradycardic activities of Isradipine.]
[D07XC04, diflucortolone, The metabolism of Ruxolitinib can be increased when combined with Difluocortolone.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C01AA05, digoxin, Ruxolitinib may increase the bradycardic activities of Digoxin.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ruxolitinib.]
[C04AE04, dihydroergocristine, The metabolism of Ruxolitinib can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Ruxolitinib can be decreased when combined with Dihydroergotamine.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ruxolitinib.]
[J05AE08, atazanavir, The metabolism of Ruxolitinib can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Ruxolitinib can be decreased when combined with Treprostinil.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Ruxolitinib.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Pramocaine.]
[C08DB01, diltiazem, Ruxolitinib may increase the bradycardic activities of Diltiazem.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, The metabolism of Ruxolitinib can be decreased when combined with Dimethyl sulfoxide.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C05CA03, diosmin, The metabolism of Ruxolitinib can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Ruxolitinib can be decreased when combined with Quazepam.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Ruxolitinib.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ruxolitinib.]
[A03FA02, cisapride, The metabolism of Ruxolitinib can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Ruxolitinib.]
[S01AX06, resorcinol, Ruxolitinib may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab.]
[S02AA12, rifamycin SV, The metabolism of Ruxolitinib can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Ruxolitinib can be increased when combined with Rifapentine.]
[R06AE09, levocetirizine, Levocetirizine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Ruxolitinib.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Ruxolitinib.]
[A04AD12, aprepitant, The metabolism of Ruxolitinib can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Ruxolitinib.]
[J05AE07, fosamprenavir, The metabolism of Ruxolitinib can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C01EB18, ranolazine, The metabolism of Ruxolitinib can be decreased when combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ruxolitinib.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06AA12, doxepin, Doxepin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01DB01, doxorubicin, The metabolism of Ruxolitinib can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06AB06, sertraline, The metabolism of Ruxolitinib can be decreased when combined with Sertraline.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Ruxolitinib can be decreased when combined with Simvastatin.]
[A12CA02, sodium sulfate, Ruxolitinib may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C07AB13, talinolol, Ruxolitinib may increase the bradycardic activities of Talinolol.]
[H01AA01, corticotropin, The metabolism of Ruxolitinib can be increased when combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Ruxolitinib.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[D01BA02, terbinafine, The metabolism of Ruxolitinib can be increased when combined with Terbinafine.]
[G04BD05, terodiline, Ruxolitinib may increase the bradycardic activities of Terodiline.]
[C07AA16, tertatolol, Ruxolitinib may increase the bradycardic activities of Tertatolol.]
[M01AG02, tolfenamic acid, Ruxolitinib may increase the bradycardic activities of Tolfenamic acid.]
[N06AG03, toloxatone, Ruxolitinib may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N03AX11, topiramate, The metabolism of Ruxolitinib can be increased when combined with Topiramate.]
[C03CA04, torsemide, The metabolism of Ruxolitinib can be decreased when combined with Torasemide.]
[N05CC01, chloral hydrate, Chloral hydrate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Ruxolitinib.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Ruxolitinib.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Ruxolitinib.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Ruxolitinib.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Ruxolitinib.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C08CA12, mepirodipine, Ruxolitinib may increase the bradycardic activities of Barnidipine.]
[S01EA01, epinephrine, The metabolism of Ruxolitinib can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Ruxolitinib.]
[N05CF02, zolpidem, The metabolism of Ruxolitinib can be decreased when combined with Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N03AX15, zonisamide, Ruxolitinib may increase the bradycardic activities of Zonisamide.]
[N05CF01, zopiclone, The metabolism of Ruxolitinib can be decreased when combined with Zopiclone.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Ruxolitinib.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ruxolitinib.]
[C02AC02, guanfacine, Ruxolitinib may increase the bradycardic activities of Guanfacine.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Ruxolitinib.]
[N02CA02, ergotamine, The metabolism of Ruxolitinib can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Ruxolitinib may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Ruxolitinib can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Ruxolitinib.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J04AK02, ethambutol, The metabolism of Ruxolitinib can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Ruxolitinib can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Ruxolitinib can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Ruxolitinib can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L02AA03, ethinyl estradiol, The metabolism of Ruxolitinib can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N03AD01, ethosuximide, Ruxolitinib may increase the bradycardic activities of Ethosuximide.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Etidocaine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Ruxolitinib.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Ruxolitinib.]
[R06AX11, astemizole, The metabolism of Ruxolitinib can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Ruxolitinib can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06AX12, bupropion, Bupropion may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06AB08, fluvoxamine, The metabolism of Ruxolitinib can be decreased when combined with Fluvoxamine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Ruxolitinib.]
[M01CB01, gold sodium thiomalate, Ruxolitinib may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Ruxolitinib may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ruxolitinib.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Ruxolitinib can be decreased when combined with Albendazole.]
[C08CA02, felodipine, Ruxolitinib may increase the bradycardic activities of Felodipine.]
[C08EA01, fendiline, Ruxolitinib may increase the bradycardic activities of Fendiline.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N02AB03, fentanyl, Ruxolitinib may increase the bradycardic activities of Fentanyl.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Ruxolitinib.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Ruxolitinib.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Ruxolitinib.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C01BC04, flecainide, The metabolism of Ruxolitinib can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01CF05, floxacillin, The metabolism of Ruxolitinib can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Ruxolitinib can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Ruxolitinib.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ruxolitinib.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N07CA03, flunarizine, Ruxolitinib may increase the bradycardic activities of Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Ruxolitinib can be decreased when combined with Flunitrazepam.]
[D07AC08, fluocinonide, The metabolism of Ruxolitinib can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Ruxolitinib can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Ruxolitinib can be increased when combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Ruxolitinib can be decreased when combined with Floxuridine.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Ruxolitinib.]
[L01BC02, fluorouracil, The metabolism of Ruxolitinib can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The metabolism of Ruxolitinib can be decreased when combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ruxolitinib.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05AG01, fluspirilene, Ruxolitinib may increase the bradycardic activities of Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01BC03, tegafur, Ruxolitinib may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[J05AE10, darunavir, The serum concentration of Ruxolitinib can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06DA04, galantamine, Ruxolitinib may increase the bradycardic activities of Galantamine.]
[C08DA02, gallopamil, Ruxolitinib may increase the bradycardic activities of Gallopamil.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N03AA04, barbexaclone, The metabolism of Ruxolitinib can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, The metabolism of Ruxolitinib can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Telavancin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01EA02, dasatinib, The metabolism of Ruxolitinib can be decreased when combined with Dasatinib.]
[J05AG04, etravirine, The metabolism of Ruxolitinib can be increased when combined with Etravirine.]
[N03AD03, methsuximide, Ruxolitinib may increase the bradycardic activities of Methsuximide.]
[N01AH02, alfentanil, Ruxolitinib may increase the bradycardic activities of Alfentanil.]
[L01EH01, lapatinib, The metabolism of Ruxolitinib can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Ruxolitinib can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Ruxolitinib can be decreased when combined with Gliclazide.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Ruxolitinib may increase the bradycardic activities of Dexmedetomidine.]
[C02CA04, doxazosin, The metabolism of Ruxolitinib can be decreased when combined with Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ruxolitinib.]
[L01EX02, sorafenib, The metabolism of Ruxolitinib can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, Ruxolitinib may increase the bradycardic activities of Esmolol.]
[M01CB04, aurothioglucose, Ruxolitinib may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Ruxolitinib.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[D01BA01, griseofulvin, The metabolism of Ruxolitinib can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Ruxolitinib.]
[N01AB01, halothane, The metabolism of Ruxolitinib can be decreased when combined with Halothane.]
[N05AH04, quetiapine, Quetiapine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06BX13, idebenone, Ruxolitinib may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ruxolitinib.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Ruxolitinib.]
[C09CA01, losartan, The metabolism of Ruxolitinib can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Ruxolitinib.]
[G03DC01, allylestrenol, The metabolism of Ruxolitinib can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Ruxolitinib.]
[N05CA16, hexobarbital, The metabolism of Ruxolitinib can be decreased when combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Ruxolitinib can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, Ruxolitinib may increase the bradycardic activities of Nilvadipine.]
[M02AA26, nimesulide, Ruxolitinib may increase the bradycardic activities of Nimesulide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C02DB02, hydralazine, The metabolism of Ruxolitinib can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[S02BA01, hydrocortisone, The metabolism of Ruxolitinib can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Ruxolitinib may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD06, propiverine, Ruxolitinib may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ruxolitinib.]
[B05AA07, hetastarch, Ruxolitinib may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ruxolitinib.]
[J04AB04, rifabutin, The metabolism of Ruxolitinib can be increased when combined with Rifabutin.]
[S01BA13, rimexolone, The metabolism of Ruxolitinib can be increased when combined with Rimexolone.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B05XA08, sodium acetate, Ruxolitinib may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Ruxolitinib.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Ruxolitinib.]
[L01AA06, ifosfamide, The metabolism of Ruxolitinib can be increased when combined with Ifosfamide.]
[N01AH03, sufentanil, Ruxolitinib may increase the bradycardic activities of Sufentanil.]
[N06AA02, imipramine, Imipramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01CD01, paclitaxel, The metabolism of Ruxolitinib can be increased when combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Tixocortol.]
[M03BX02, tizanidine, Ruxolitinib may increase the bradycardic activities of Tizanidine.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Ruxolitinib.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ruxolitinib.]
[A11HA07, inositol, Ruxolitinib may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ruxolitinib.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ruxolitinib.]
[N06AX17, milnacipran, The metabolism of Ruxolitinib can be decreased when combined with Milnacipran.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Ruxolitinib.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Articaine.]
[A10BH01, sitagliptin, Sitagliptin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C10AA06, cerivastatin, The metabolism of Ruxolitinib can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Ruxolitinib.]
[C07AA01, alprenolol, Ruxolitinib may increase the bradycardic activities of Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ruxolitinib.]
[V03AB01, ipecac, Ruxolitinib may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AF05, iproniazid, The metabolism of Ruxolitinib can be decreased when combined with Iproniazid.]
[P01AX06, atovaquone, The metabolism of Ruxolitinib can be decreased when combined with Atovaquone.]
[J04AC01, isoniazid, The metabolism of Ruxolitinib can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Ruxolitinib may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Ruxolitinib.]
[S01AA24, kanamycin, Ruxolitinib may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Ruxolitinib can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Ruxolitinib.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Ruxolitinib.]
[J02AB02, ketoconazole, The metabolism of Ruxolitinib can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Ruxolitinib can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The metabolism of Ruxolitinib can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[V03AC03, deferasirox, The metabolism of Ruxolitinib can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Ruxolitinib can be increased when combined with Abatacept.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C07AG01, labetalol, Ruxolitinib may increase the bradycardic activities of Labetalol.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N03AX18, lacosamide, Ruxolitinib may increase the bradycardic activities of Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Ruxolitinib.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Lidocaine.]
[C08EX01, lidoflazine, Ruxolitinib may increase the bradycardic activities of Lidoflazine.]
[S01AA21, amikacin, Ruxolitinib may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Ruxolitinib can be increased when combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Ruxolitinib.]
[A07DA03, loperamide, Ruxolitinib may increase the bradycardic activities of Loperamide.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Ruxolitinib can be decreased when combined with Lovastatin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Ruxolitinib.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Temsirolimus is combined with Ruxolitinib.]
[B05XA11, magnesium chloride, Ruxolitinib may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Ruxolitinib may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, Ruxolitinib may increase the bradycardic activities of Magnesium sulfate.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ruxolitinib.]
[L01EA03, nilotinib, The metabolism of Ruxolitinib can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ruxolitinib.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Ruxolitinib.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Ruxolitinib.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Ruxolitinib.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Ruxolitinib.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N02AB02, meperidine, The metabolism of Ruxolitinib can be decreased when combined with Meperidine.]
[N03AB04, mephenytoin, The metabolism of Ruxolitinib can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Ruxolitinib can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Mepivacaine.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The metabolism of Ruxolitinib can be increased when combined with Aminoglutethimide.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Paliperidone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[H01CB03, lanreotide, Ruxolitinib may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The metabolism of Ruxolitinib can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The metabolism of Ruxolitinib can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ruxolitinib.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Ruxolitinib.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Ruxolitinib can be decreased when combined with Methoxyflurane.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Ruxolitinib may increase the bradycardic activities of Methyldopa.]
[V04CG05, methylene blue, The metabolism of Ruxolitinib can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Ruxolitinib can be decreased when combined with Methylergometrine.]
[H02AB04, methylprednisolone, The metabolism of Ruxolitinib can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Ruxolitinib can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, Methyltestosterone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N02CA04, methysergide, The metabolism of Ruxolitinib can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, Metoclopramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Ruxolitinib may increase the bradycardic activities of Metoprolol.]
[P01AB01, metronidazole, The metabolism of Ruxolitinib can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Ruxolitinib can be increased when combined with Metyrapone.]
[S02AA13, miconazole, The metabolism of Ruxolitinib can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Ruxolitinib.]
[N05CD08, midazolam, The metabolism of Ruxolitinib can be decreased when combined with Midazolam.]
[C01CA17, midodrine, Ruxolitinib may increase the bradycardic activities of Midodrine.]
[G03XB01, mifepristone, The metabolism of Ruxolitinib can be increased when combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Ruxolitinib.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C09CA03, valsartan, The metabolism of Ruxolitinib can be decreased when combined with Valsartan.]
[J01FA11, miocamycin, The metabolism of Ruxolitinib can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Ruxolitinib can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ruxolitinib.]
[L03AC01, aldesleukin, The metabolism of Ruxolitinib can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Ruxolitinib can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Ruxolitinib can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Ammonium chloride may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ruxolitinib.]
[L01EX03, pazopanib, The metabolism of Ruxolitinib can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ruxolitinib.]
[N05CA02, amobarbital, The metabolism of Ruxolitinib can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The metabolism of Ruxolitinib can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Ruxolitinib can be decreased when combined with Raloxifene.]
[N03AB05, fosphenytoin, The metabolism of Ruxolitinib can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ruxolitinib.]
[C07AA12, nadolol, Ruxolitinib may increase the bradycardic activities of Nadolol.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01CF06, nafcillin, The metabolism of Ruxolitinib can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Ruxolitinib can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Ruxolitinib can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A10BG01, troglitazone, The metabolism of Ruxolitinib can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, Duloxetine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ruxolitinib.]
[L01CD02, docetaxel, The metabolism of Ruxolitinib can be decreased when combined with Docetaxel.]
[S03AA01, neomycin, Ruxolitinib may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, Ruxolitinib may increase the bradycardic activities of Remifentanil.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Ruxolitinib.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[S01AA23, netilmicin, Ruxolitinib may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Ruxolitinib can be decreased when combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Ruxolitinib.]
[C10AD02, niacin, The metabolism of Ruxolitinib can be decreased when combined with Niacin.]
[C08CA04, nicardipine, Ruxolitinib may increase the bradycardic activities of Nicardipine.]
[P02DA01, niclosamide, The metabolism of Ruxolitinib can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, Ruxolitinib may increase the bradycardic activities of Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C08CA06, nimodipine, Ruxolitinib may increase the bradycardic activities of Nimodipine.]
[C08CA07, nisoldipine, Ruxolitinib may increase the bradycardic activities of Nisoldipine.]
[C08CA08, nitrendipine, Ruxolitinib may increase the bradycardic activities of Nitrendipine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G03DC02, norethindrone, The metabolism of Ruxolitinib can be decreased when combined with Norethisterone.]
[C02KX01, bosentan, The metabolism of Ruxolitinib can be increased when combined with Bosentan.]
[R05DA07, noscapine, The metabolism of Ruxolitinib can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Ruxolitinib.]
[G02CA02, nylidrin, Ruxolitinib may increase the bradycardic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Ruxolitinib.]
[H01CB02, octreotide, The serum concentration of Ruxolitinib can be increased when it is combined with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Ruxolitinib can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Ruxolitinib can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Ruxolitinib can be increased when combined with Omeprazole.]
[N02AA02, opium, Ruxolitinib may decrease the excretion rate of Opium which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Ruxolitinib.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Ruxolitinib.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A14AA08, oxandrolone, The metabolism of Ruxolitinib can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C07AA02, oxprenolol, Ruxolitinib may increase the bradycardic activities of Oxprenolol.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Ruxolitinib.]
[J04AB30, capreomycin, Ruxolitinib may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[H02AB05, paramethasone, The metabolism of Ruxolitinib can be increased when combined with Paramethasone.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD11, fesoterodine, Fesoterodine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C07AA23, penbutolol, Ruxolitinib may increase the bradycardic activities of Penbutolol.]
[N05AG03, penfluridol, Ruxolitinib may increase the bradycardic activities of Penfluridol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Ruxolitinib.]
[J01CE09, penicillin G procaine, Ruxolitinib may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ruxolitinib.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ruxolitinib.]
[N05CA01, pentobarbital, The metabolism of Ruxolitinib can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Ruxolitinib.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Ruxolitinib.]
[C08EX02, perhexiline, Ruxolitinib may increase the bradycardic activities of Perhexiline.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ruxolitinib.]
[N02BE03, phenacetin, The metabolism of Ruxolitinib can be decreased when combined with Phenacetin.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Ruxolitinib.]
[N03AA02, phenobarbital, The metabolism of Ruxolitinib can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Ruxolitinib.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[M02AA01, phenylbutazone, The metabolism of Ruxolitinib can be increased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The metabolism of Ruxolitinib can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Ruxolitinib can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[L02BB03, bicalutamide, The metabolism of Ruxolitinib can be decreased when combined with Bicalutamide.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C08CX01, mibefradil, Ruxolitinib may increase the bradycardic activities of Mibefradil.]
[N05AG02, pimozide, The metabolism of Ruxolitinib can be decreased when combined with Pimozide.]
[C07AA03, pindolol, Ruxolitinib may increase the bradycardic activities of Pindolol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Ruxolitinib can be decreased when combined with Saquinavir.]
[N06BX03, piracetam, Ruxolitinib may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J05AG02, delavirdine, The metabolism of Ruxolitinib can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Ruxolitinib can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Ruxolitinib.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Ruxolitinib.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A03AE01, alosetron, The metabolism of Ruxolitinib can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Ruxolitinib can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The metabolism of Ruxolitinib can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, Saxagliptin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Ruxolitinib.]
[C10AA08, pitavastatin, The metabolism of Ruxolitinib can be decreased when combined with Pitavastatin.]
[C07AB01, practolol, Ruxolitinib may increase the bradycardic activities of Practolol.]
[S03BA02, prednisolone, The metabolism of Ruxolitinib can be increased when combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Ruxolitinib.]
[C01DX02, prenylamine, Ruxolitinib may increase the bradycardic activities of Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Ruxolitinib can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Ruxolitinib can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Ruxolitinib can be increased when combined with Probenecid.]
[C01BA02, procainamide, Ruxolitinib may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Ruxolitinib.]
[C10AB05, fenofibrate, The metabolism of Ruxolitinib can be decreased when combined with Fenofibrate.]
[G03DA04, progesterone, The metabolism of Ruxolitinib can be decreased when combined with Progesterone.]
[N05AA03, promazine, The metabolism of Ruxolitinib can be decreased when combined with Promazine.]
[R06AD02, promethazine, The metabolism of Ruxolitinib can be decreased when combined with Promethazine.]
[C01BC03, propafenone, Ruxolitinib may increase the bradycardic activities of Propafenone.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N01AX10, propofol, The metabolism of Ruxolitinib can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Ruxolitinib can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Ruxolitinib may increase the bradycardic activities of Propranolol.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ruxolitinib.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Ruxolitinib.]
[R03DC03, montelukast, The metabolism of Ruxolitinib can be decreased when combined with Montelukast.]
[N07XX07, dalfampridine, Dalfampridine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[P02CC01, pyrantel, Ruxolitinib may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Ruxolitinib.]
[C01BA01, quinidine, The metabolism of Ruxolitinib can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Ruxolitinib can be increased when combined with Quinine.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Ruxolitinib can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Ruxolitinib can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ruxolitinib.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[N05CA06, secobarbital, The metabolism of Ruxolitinib can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Ruxolitinib can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Obinutuzumab.]
[J01GB08, sisomicin, Ruxolitinib may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Ruxolitinib may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Ruxolitinib.]
[H01CB01, somatostatin, The metabolism of Ruxolitinib can be decreased when combined with Somatostatin.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[C07AA07, sotalol, Ruxolitinib may increase the bradycardic activities of Sotalol.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ruxolitinib.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ruxolitinib.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AG01, valproic acid, The metabolism of Ruxolitinib can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The metabolism of Ruxolitinib can be increased when combined with Hydrocortisone butyrate.]
